PHARMACOLOGY OF ANTIDEPRESSANTS AND MOOD STABILIZERS Philip G. Janicak, MD Professor of Psychiatry Rush University I. Introduction II. Diagnostic Indication for Antidepressants A) Major Depressive Disorder • Mood • Behavior • Cognitive B) Dysthymic Disorder C) Bipolar I Disorder • Depressed or mixed episode D) Bipolar II Disorder • Depressed or mixed episode E) Cyclothymic Disorder F) Other Disorders • Schizoaffective, bipolar or depressed type • Due to a General Medical Condition • Substance-induced III. Pharmacodynamics of Antidepressants A) Serotonin (5-HT) • SSRI (e.g., fluoxetine) • SARI (e.g., nefazodone) B) Catecholamine (NE; DA) • NDRI (e.g., bupropion) • SNRI (e.g., reboxetine) C) Serotonin/Catecholamine • TCA (e.g., imipramine) • MAO-I (e.g., phenelzine) • SSNRI (e.g., venlafaxine) • NaSSA (e.g., mirtazapine) IV. Adverse Effects and Drug Interactions of AntidepressantsV. Treatment Strategy for Major Depression VI. Diagnostic Indications for Mood Stabilizers A) Bipolar Disorder • General Considerations B) Treatment of Bipolar Disorder VII. Pharmacodynamics of Mood Stabilizers A) Lithium B) Anticonvulsants • Valproate • Carbamazepine • Others C) Novel Antipsychotics • Olanzapine • Others VIII. Adverse Effects, Pharmacokinetics and Drug Interactions and of Mood Stabilizers IX. Treatment Strategy for Acute Mania X.
View Full Document
Unlocking...